BCR/ABL1, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Reflex
Use
This test is useful for the diagnostic workup of patients with a high probability of BCR-ABL1-positive hematopoietic neoplasms, particularly chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia (B-lymphoblastic leukemia). It provides a pretreatment quantitative level of BCR-ABL1 mRNA transcript if the initial diagnostic reverse transcription polymerase chain reaction screen is positive. When positive, the reflex test provides a quantitative value for the corresponding e13-a2 or e14-a2 (p210) BCR-ABL1 mRNA fusion variant.
Special Instructions
Not provided.
Limitations
Results of this assay cannot be directly compared with results from other PCR assays. Monitoring should be done using the same method and laboratory. Quantitative testing for rare transcripts like e19-a2/p230 is not available. Normalized BCR-ABL1/ABL1 values below 1% are not considered reliable and require submission of a new specimen for accurate quantification using the specific BCRAB test.
New York Approved
Methodology
PCR-based (RT-PCR)
Biomarkers
BCR, ABL1
Gene
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10 mL
Minimum Volume
Not provided
Container
Lavender top (EDTA), Yellow top (ACD)
Collection Instructions
Invert several times to mix blood. Send whole blood specimen in original tube. Do not aliquot. Label specimen as blood.
Storage Instructions
Refrigerated (preferred) or Ambient within 72 hours in PURPLE OR PINK TOP/EDTA.
Causes for Rejection
Gross hemolysis, Moderately to severely clotted
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 72 hours |